|Topic:||Review of the HIVNET 012 Perinatal HIV Prevention Study|
THE NATIONAL ACADEMIES
Institute of Medicine
Board on Population Health and Public Health Practice
Committee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study
Monday, April 4, 2005
226 Dirksen Senate Office Bldg. -- 3:00 p.m.
184 Dirksen Senate Office Bldg. -- 4:30 p.m.
Thursday, April 7, 2005
2325 Rayburn House Office Bldg. -- 11:00 a.m.
727 Hart Senate Office Bldg. -- 2:00 p.m.
2125 Rayburn House Office Bldg. -- 3:30 p.m.
Review of the HIVNET 012 Perinatal HIV Prevention Study
The HIVNET 012 perinatal HIV prevention trial determined that the drug nevirapine could prevent mother-to-child transmission of HIV. This report, from the Institute of Medicine, reviews the trial's methods and data interpretation, and assesses the validity of its overall findings.
These series of briefings were for members of Congress and congressional staff only. The report was publicly released on April 8, 2005 and can be found, in its entirety, on the Web site of the National Academies Press.